Will you add this Genomic IPO to your portfolio?

I just learned about an exciting company that recently IPOed on NASDAQ. Also trading on the London Stock Exchange (LSE), MaxCyte (MXCT), announced terms for its IPO on NASDAQ July 26. The global clinical-stage cell-based medicines and life sciences company is reportedly planning to raise $150 million at a $1.3 billion market cap.

Is it worth adding to your portfolio? Find out below.

Technology

Maxcyte has developed a proprietary technology known as ExPERT that can scale the process of cellular electroporation. The technology platform "represents the next generation of the industry’s leading, clinically validated Flow Electroporation® technology for complex cellular engineering. "

What is electroporation, you ask? It is a technique in which an electrical field is applied to cells where it disrupts the cell membranes so nucleic acids can get to the inside to perform the gene-editing. For more details on its technology, please watch my video review on YouTube here .

Value Creation from Strategic Platform Licenses

Now let's take a look at their strategic platform licenses (SPLs) that they have with a number of companies that use crispr technology, including CRISPR Therapeutics, Beam Therapeutics, Editas, and Caribou Biosciences.

The company's licensing deals include significant development milestones and high-value participation in the future success of its partners.

• The potential value of pre-commercial (clinical development) milestone from SPLs exceeds $950 million

• Sales-based payments upon partner's product commercialization

• Recurring revenues from lease of instruments and sales of single-use disposables that grow with program success

• Milestone revenue is MaxCyte's highest growth revenue stream

Partners

Let's also take a look at some of the companies that have partnered with MaxCyte and are using its ExPERT electroporation flow system.

CRISPR Therapeutics is using MaxCyte's ExPERT for hemoglobin-related diseases and severe combined immunodeficiency (SCID), as well as in immuno-oncology. Editas Medicine uses it for sickle cell disease, beta-thalassemia, and immuno-oncology. It is being used for oncology (CAR-T) by Kite Pharma (now Gilead) and ALlogene Therapeutics. Additionally, Precision Biosciences, VOR Biopharma, KSQ Therapeutics, Caribou Biosciences, Apeiron Biologics, Myeloid Therapeutics, and Celularity use it for oncology purposes. Meanwhile, Beam Therapeutics, which also uses electroporation for its hematology and oncology programs, reportedly uses MaxCyte's ExPERT machine.

Overall, I like MaxCyte and the fact that they are using a technique known as electroporation that can be useful for a number of genomic companies, such as Beam Therapeutics, CRISPR Therapeutics, and Caribou Biosciences, among others.

MaxCyte is a very exciting company and I think it's a pick-and-shovel play within the space.

I'm glad that you have learned about it and trusting that this review helps you decide if it is worth adding to your portfolio.